Sanofi Patent-Cliff Exposure & CMS Drug Spending Portfolio
Sanofi (Bridgewater, NJ): 66 reconciled FDA prescription therapies (1.7% 2025 to 2030 cliff risk), $4.79B 2024 CMS Part D & Medicaid spend, and 59 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Bridgewater, NJ |
| Reconciled FDA Portfolio Therapies | 66 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 1.7% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $4.79B |
| 2024 Medicare Part D Spend | $3.53B |
| 2024 Medicaid Spend | $1.26B |
| California HCAI SB 17 Filings | 59 WAC filings (max 52.7% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.